In recent years, ciliary trans-scleral cyclophotocoagulation has been adopted as a helpful intervention for challenging cases of recalcitrant glaucoma. The procedure is usually performed with contact fibreoptic delivery of either infrared (1064 nm) neodymium/YAG or nearinfrared (about 810 nm) diode laser light energy, with the latter being a widely available method. A California company (IRIDEX Corporation, IRIS Medical Instruments, Mountain View, CA, USA) developed for use with their diode laser eye treatment console a hemisphere-tipped 400 mm diameter fibreoptic delivery device specifically for trans-scleral cyclophotocoagulationFthe G-Probe. While treatment with the G-Probe has become popular, the stipulation by the US Food & Drug Administration that it be packaged and sold as a single-use device 1 imposes costly impediments to usage. Some physicians reuse the probes.
Several questions arise when considering the reuse of G-Probes. The first is whether a probe after use for a glaucoma treatment has reduced output.
2 Is the fibre changed by delivering light to the surface of the eye? The second is whether cleansing or sterilizing a probe after use for a treatment affects its function during a subsequent procedure. Another issue is sterility of the probe after use and cleansing.
In a thoughtful study reported in this issue of the journal, Hossain et al 3 assess practice patterns in the United Kingdom regarding the reuse of G-Probes, and they present an inventive method to measure probe output. They report a widespread reuse of G-Probes, so it makes sense that they also identify a clinically feasible way to assess probe function after previous use. They detail, and test, a method to measure diode laser burns on patches printed on paper in stepwise depths of grey; they assess the performance of five new probes; and they compare a single probe after use for six clinical treatments with a new probe. The output of the used probe is reduced compared with the new probe. They carefully cleanse probes with alcohol between use, which is probably a widespread practice, but their report does not address the issue of sterility.
While the method proposed in the report provides clinical guidance, their study of probe function is not quantitative, and their method of probe assessment suffers weaknesses due to physical optics considerations and printer output properties. The hemisphere tip of the fibreoptic of the probe has a radius of curvature of 200 mm. This creates a lens with a focal length of 0.4 mm (lens power 2500 D) when light exits the fibre into air. Their probe holder places the tip of the fibre 2 mm from the target paper, so the cross-section of the beam at the paper has a calculated diameter of 1.6 mm and an area of 2.01 mm 2 . A variation of only 0.2 mm in fibre location would alter the area of the spot size by about 25% (ranging from diameter 1.4 mm and area 1.54 mm 2 for the fibre too close by 0.2 mm up to diameter 1.8 mm and area 2.54 mm 2 for the fibre too distant by 0.2 mm). This may explain why the new probe used for comparison with the used probe in the third part of the authors' report differed in spot diameter from the five probes in the second part of the report.
There is loss of light energy output at the tip from total internal reflection upon testing a fibreoptic in air. This loss is reduced by the index of refraction matching, such as occurs when the probe tip is linked to ocular tissue by intervening conjunctival surface lubricating fluid, as recommended by the manufacturer. 1 Finally, there is potential variation in the printed grey-scale density when different printers receive the same digital instructions or the same printer at different times. This can arise from differences in ink composition or paper composition. For example, my printer at 'scale 8' probably does not replicate yours.
